# PRESS CONFERENCE SCHEDULE

Conference on Retroviruses and Opportunistic Infections/CROI 2018

All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are ET.

This press conference may be viewed live at https://zoom.us/j/408375781 or accessed by phone toll-free from the U.S. at 877-853-5247 or 877-369-0926; Webinar ID: 408 375 781; International telephone access numbers [here](#).

### Sunday, March 4, 3:00 – 4:00 pm

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 – 3:15 pm</td>
<td>Chaired by Judith Currier, CROI Chair and University of California Los Angeles, CA, US</td>
</tr>
<tr>
<td><strong>WELCOME AND OVERVIEW OF CROI 2018</strong></td>
<td></td>
</tr>
<tr>
<td>Judith Currier, CROI Chair and University of California Los Angeles, CA, US</td>
<td></td>
</tr>
<tr>
<td>Richard Koup, CROI Vice Chair and National Institute of Allergy and Infectious Diseases, US</td>
<td></td>
</tr>
<tr>
<td>– and –</td>
<td></td>
</tr>
<tr>
<td>Sharon Hillier, CROI Vice Chair and Univ of Pittsburgh, Pittsburgh, PA, US</td>
<td></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSION 4 -- SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES</strong></td>
<td></td>
</tr>
<tr>
<td>(PRESENTED MONDAY, MARCH 5 10:00 AM - 12:00 PM)</td>
<td></td>
</tr>
<tr>
<td>(EMBARGO ON THESE STUDIES LIFTS SUNDAY, MARCH 4, 3:35 PM ET)</td>
<td></td>
</tr>
<tr>
<td>42. Phylogenetic Patterns of HIV Transmission Among Transgender Women in Los Angeles</td>
<td>Manon Ragonnet-Cronin, University of California, San Diego, CA, US</td>
</tr>
<tr>
<td>45. Female HIV Acquisition per Sex Act is Elevated in Late Pregnancy and Postpartum</td>
<td>Renee Heffron, University of Washington, Seattle, WA, US</td>
</tr>
<tr>
<td>3:35 – 4:00 PM</td>
<td>Chaired by John Mellors, University of Pittsburgh School of Medicine, Pittsburgh, PA, US</td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSION 5 -- THE HIV RESERVOIR AND VIRAL REPLICATION</strong></td>
<td></td>
</tr>
<tr>
<td>(PRESENTED TUESDAY, MARCH 6 10:00 AM - 12:00 PM)</td>
<td></td>
</tr>
<tr>
<td>(EMBARGO ON THESE STUDIES LIFTS SUNDAY, MARCH 4, 4:00 PM ET)</td>
<td></td>
</tr>
<tr>
<td>70. No Evidence for Ongoing HIV Replication in Lymph Nodes During Suppressive ART</td>
<td>Mary Kearney, National Cancer Institute, National Institutes of Health, US</td>
</tr>
<tr>
<td>71. No Residual Virus Replication in a Randomised Trial of Dolutegravir Intensification</td>
<td>Thomas Rasmussen, Aarhus University Hospital, Denmark</td>
</tr>
<tr>
<td>72. Single Romidepsin Infusions Do Not Increase HIV Expression in Persons on ART (A5315)</td>
<td>Deborah McMahon, University of Pittsburgh, PA, US</td>
</tr>
<tr>
<td>73LB. PGT121 Combined with GS-9620 Delays Viral Rebound in SHIV-infected Rhesus Monkeys</td>
<td>Dan Barouch, Beth Israel Deaconess Medical Center, Boston, MA, US</td>
</tr>
</tbody>
</table>
Conference on Retroviruses and Opportunistic Infections/CROI 2018

All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are ET.

This press conference may be viewed live at https://zoom.us/j/587699641 or accessed by phone toll-free from the U.S. at 877-853-5247 or 877-369-0926; Webinar ID: 587 699 641; International telephone access numbers here.

Monday, March 5, 12:15 – 1:15 pm

12:15 – 12:45 PM  Chaired by Diane Havlir, University of California San Francisco, CA, US

**ORAL ABSTRACT SESSION 2 – ART: NEW DATA AND NEW INSIGHTS**
(PRESENTED MONDAY, MARCH 5, 10:00 AM - 12:00 PM)

22. Switch to Bictegravir/F/TAF from DTG and ABC/3TC
Jean-Michel Molina, Hôpital Saint-Louis, Paris, France

23. Impact of Raltegravir Intensification of First-line ART on IRIS in the REALITY Trial
Diana Gibb, MRC Clinical Trials Unit at UCL, London, UK

24. Hair Antiretroviral Levels Strongly Predict Virologic Outcomes in ACTG's A5257 Trial
Monica Gandhi, University of California San Francisco, CA, US

30LB. Results of ACTG A5288: A Strategy Study in RLS for 3rd-line ART Candidates
Beatriz Grinsztejn, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil

12:45– 1:15 PM  Chaired by Constance Benson, University of California San Diego, CA, US

**ORAL ABSTRACT SESSION 3 – ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION**
(PRESENTED MONDAY, MARCH 5, 10:00 AM - 12:00 PM)

33. Safety And Efficacy Of Dolutegravir-based ART In TB/HIV Coinfected Adults at Week 24
Kelly Dooley, Johns Hopkins University, Baltimore, MD, US

37LB. One Month Of Rifapentine/Isoniazid to Prevent TB In People with HIV: Brief-TB/A5279
Richard Chaissen, Johns Hopkins University, Baltimore, MD, US

38LB. Urine-Based Screening For Tuberculosis: A Randomized Trial In HIV-Positive Inpatients
Ankur Gupta-Wright, London School of Hygiene & Tropical Medicine, London, UK

39LB. A Randomized Controlled Trial Of High-Dose Rifampin For Pulmonary Tuberculosis
Gustavo Velásquez, Brigham and Women's Hospital, Boston, MA, US
Conference on Retroviruses and Opportunistic Infections/CROI 2018

All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are ET. CROI press conferences are simulcast on http://www.croiconference.org/.

This press conference may be viewed live at https://zoom.us/j/758422618 or accessed by phone toll-free from the U.S. at 877-853-5247 or 877-369-0926; Webinar ID: 758 422 618; International telephone access numbers here.

Tuesday, March 6, 12:15 – 1:30 pm

12:15 – 12:35 PM  Chairman by Kevin De Cock, Centers for Disease Control and Prevention, Kenya

**ORAL ABSTRACT SESSION 8 – 90:90:90: PROGRESS, CHALLENGES, AND NEW TOOLS**
(PRESENTED TUESDAY, MARCH 6, 10:00 AM - 12:00 PM)

91. Progress Toward 90-90-90: 2016 Lesotho Population-Based HIV Impact Assessment Results
Kyaw Thin, Ministry of Health, Maseru, Lesotho

94. Same-Day Art Initiation After Home-Based HIV Testing: A Randomized Controlled Trial
Niklaus Labhardt, Swiss Tropical and Public Health Institute, Basel, Switzerland

96. Extended-Release Naltrexone Improves Viral Suppression In HIV+ Prisoners
Sandra Springer, Yale School of Medicine, New Haven, CT, US

12:35 – 1:00 PM  Chairman by Judith Currier, University of California Los Angeles, CA, US

**ORAL ABSTRACT SESSION 6 – NON-AIDS COMPLICATIONS**
(PRESENTED TUESDAY, MARCH 6, 10:00 AM - 12:00 PM)

75. Serious Clinical Outcomes In HIV-Positive Persons With Chronic Kidney Disease (CKD)
Lene Ryom, Rigshospitalet, Copenhagen, Denmark

76. Increased Risk Of Peripheral Artery Disease In Persons With HIV Compared To Controls
Andreas Knudsen, Rigshospitalet, Copenhagen, Denmark

77. HIV Infection Is Associated With Progression Of High Risk Coronary Plaque In The MACS
Wendy Post, Johns Hopkins University, Baltimore, MD, US

80. Platelet Function upon Switching to TAF vs. Continuing ABC: A Randomized Substudy
Patrick Mallon, University College Dublin, Ireland

1:00 – 1:30 PM  Chairman by Susan Buchbinder, University of California San Francisco, CA, US

**ORAL ABSTRACT SESSION 7 – OF MICE, MONKEYS, AND MEN: PREP FROM PRECLINICAL TO POPULATION LEVEL IMPACT**
(PRESENTED TUESDAY, MARCH 6, 10:00 AM - 12:00 PM)

**-and-**

**ORAL ABSTRACT SESSION 13 – IMPROVING USE OF THE TOOLS WE HAVE: HIV TESTING AND VAGINAL RINGS**
(PRESENTED WEDNESDAY, MARCH 7, 10:00 AM - 12:00 PM)
(EMBARGO ON THESE STUDIES LIFTS TUESDAY, MARCH 6, 1:30 PM ET)
ORAL ABSTRACT SESSION 7 – OF MICE, MONKEYS, AND MEN: PrEP FROM PRECLINICAL TO POPULATION LEVEL IMPACT

85. Oral FTC/TAF Combination Prevents Vaginal SHIV Infection In Pigtail Macaques
Ivana Massud, Centers for Disease Control and Prevention, Atlanta, GA, US

Dawn Smith, Centers for Disease Control and Prevention, Atlanta, GA, US

89LB. Low Dose MK-8591 Protects Rhesus Macaques Against Rectal SHIV Infection
Martin Markowitz, Aaron Diamond AIDS Research Center, New York, NY US

ORAL ABSTRACT SESSION 13 – IMPROVING USE OF THE TOOLS WE HAVE: HIV TESTING AND VAGINAL RINGS

143LB. High Uptake And Reduced HIV-1 Incidence in an Open-Label Trial of the Dapivirine Ring
Jared Baeten, University of Washington, Seattle, WA, US

144LB. HIV Incidence and Adherence in DREAM: An Open-Label Trial of Dapivirine Vaginal Ring
Zeda Rosenberg, International Partnership for Microbicides, Silver Spring, MD, US
All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are ET.

This press conference may be viewed live at https://zoom.us/j/274264195 or accessed by phone toll-free from the U.S. at 877-853-5247 or 877-369-0926; Webinar ID: 274 264 195; International telephone access numbers here.

Wednesday, March 7, 12:15 – 1:15 pm

12:15 – 12:40 PM Chaired by James McIntyre, Anova Health Institute, Johannesburg, South Africa

ORAL ABSTRACT SESSION 12 – CRITICAL ISSUES IN WOMEN'S HEALTH AND EARLY TREATMENT OF Pediatric HIV INFECTION
(PRESENTED WEDNESDAY, MARCH 7, 10:00 AM - 12:00 PM)

135. ARV Prophylaxis/ART Initiation at Birth Limits the Size of the Reservoir in Children
Marta Massanella, Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada

137. Time To Viral Rebound After Stopping ART In Children Treated from Infancy in CHER
Man Chan, University College London, UK

141. Vaginal Contraceptive Hormone Exposure Profoundly Altered by EFV- and ATV/R-Based ART
Kimberly Scarsi, University of Nebraska Medical Center, Omaha, NE, US

142LB. Randomized Trial of Safety of Isoniazid Preventive Therapy During or After Pregnancy
Amita Gupta, Johns Hopkins University, Baltimore, MD, US

12:40 – 1:15 PM Chaired by David Thomas, Johns Hopkins School of Medicine, Baltimore, MD, US

ORAL ABSTRACT SESSION 11 – HEPATITIS C VIRUS / HIV-ASSOCIATED MALIGNANCIES
(PRESENTED WEDNESDAY, MARCH 7, 10:00 AM - 12:00 PM)

ORAL ABSTRACT SESSION 6 - NON-AIDS COMPLICATIONS
(PRESENTED TUESDAY, MARCH 6, 10:00 AM - 12:00 PM)

SYMPOSIUM SESSION 9 – EMERGING PRIORITIES IN LIVER DISEASE
(PRESENTED WEDNESDAY, MARCH 7, 4:00 PM - 6:00 PM)
(EMBARGO ON THIS PRESENTATION LIFTS WEDNESDAY, MARCH 7, 1:15 PM ET)

ORAL ABSTRACT SESSION 11 – HEPATITIS C VIRUS / HIV-ASSOCIATED MALIGNANCIES

128. 8 Weeks Of Grazoprevir/Elbasvir For Acute HCV: A Multicenter Clinical Trial (DAAHS 2)
Anne Boerekamps, Erasmus University Medical Center, Rotterdam, Netherlands

129. Fueling The Epidemic: Low Rates Of Spontaneous Clearance of Acute HCV Coinfection
Christoph Boesecke, Bonn University Hospital, Bonn, Germany

130. International Versus Domestic HCV Transmission In MSM: A Perspective for the DAA Era
Luisa Salazar-Vizcaya, University Hospital of Bern, Switzerland
ORAL ABSTRACT SESSION 6 - NON-AIDS COMPLICATIONS

81LB. A Treatment as Prevention Trial to Eliminate HCV in HIV+ MSM: the Swiss HCVree Trial
Dominique Braun, University of Zurich, Switzerland

SYMPOSIUM SESSION 9 – EMERGING PRIORITIES IN LIVER DISEASE

166. Expanding Hope: Organ Transplants From Donors With HIV or HCV Infection
Christine Durand, Johns Hopkins University, Baltimore, MD, US